Fiche centre
Princess Margaret Cancer Centre
Toronto — Canada
Essais liés10clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05152147
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Adagrasib | Cancer | Phase 2/3 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | RECRUITING |
| TBI-2001 | SEP | Phase 1 | NCT05963217 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | RECRUITING |
| Iza-bren | Cancer | Phase 2/3 | NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | RECRUITING |
| Zanidatamab | Parkinson | Phase 3 | NCT05152147 | HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | ACTIVE_NOT_RECRUITING |
| rondecabtagene autoleucel | SEP | Phase 3 | NCT07188558 | PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | RECRUITING |
| HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers | Cancer | Non applicable | NCT06487403 | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers | RECRUITING |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | COMPLETED |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |